UCB, a global biopharmaceutical company, today announced three-year data from the BE HEARD trials for BIMZELX® (bimekizumab-bkzx) in moderate-to-severe hidradenitis suppurativa (HS). BIMZELX, the ...
BridgeBio Pharma, Inc.'s Attruby (Acoramidis) delivers early, durable reductions in cumulative cardiovascular events. Learn ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback